ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

736

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
CKD
Cardiac Disease
Cardiopulmonary Bypass

Interventions

DRUG: Placebo
DRUG: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.